Business ❯ Pharmaceutical Industry ❯ Market Competition

Pricing Strategies

Generic Drugs Direct-to-Consumer Sales Novo Nordisk Consumer Access Generic Medications Consumer Impact GLP-1 Drugs Eli Lilly Drug Development Compounded Drugs Copycat Drugs Supply Chain Management CVS Health Cost Reduction Executive Orders Regulatory Actions Pharmacy Benefit Managers Novo Nordisk and Eli Lilly Product Launches Consumer Discounts Patient Access Generic Drug Launches Vaccine and Drug Development Subscription Models EMS Semaglutide Biosimilar Pricing Market Access Product Development Investor Relations Eli Lilly and Novo Nordisk Ozivy

FDA Approves Langlara as Interchangeable Biosimilar to Lantus

Pharmacy-level substitution could expand access.

Novo Nordisk to Cut U.S. List Prices for Wegovy, Ozempic and Rybelsus to $675 in 2027

Indiana Sues Eli Lilly, Alleging Scheme to Inflate Insulin Prices

Lilly Cuts Zepbound Cash Prices on LillyDirect as GLP‑1 Price Competition Deepens